- Up-to-date review on the chemistry and biology of nucleosides
- Modern synthetic methodology
- Comprehensive coverage of antiviral nucleosides

This book summarizes the recent advances in nucleosides chemistry and chemotherapy over the past 10-15 years. It covers recently discovered nucleoside antiviral agents, their therapeutic aspects and biochemistry, and also extensive reviews on their chiral synthesis.

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.

Biotechnology may be defined as the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services (Bullet al., 1982, p. 21) or as any technique that uses living organisms (or parts of organisms) to make or modify products, to improve plants or animals, or to develop microorganisms for specific use (OTC, 1988). In line with these broad definitions we can consider marine biotechnology as the use of marine organisms or their constituents for useful purposes in a controlled fashion. This series will explore a range of scientific advances in support of marine biotechnology. It will provide information on advances in three categories: (1) basic knowledge, (2) ap plied research and development, and (3) commercial and institutional issues. We hope the presentation of the topics will generate interest and interaction among readers in the academic world, government, and industry. This first volume examines chemical and biological properties of some natural products that are useful or potentially useful in research and in the chemical and pharmaceutical industries. One chapter describes a system for producing such substances on a large scale. Biotechnology incorporates molecular biology in order to go beyond tradi tional biochemical technology such as the production of antibiotic drugs from bacterial cultures in bioreactors. Development of the technology for production of antibiotics in this way resulted from fundamental advances in chemistry, phar macology, microbiology, and biochemical engineering."

Important clinical issues as the outcome of long term treatment with antidepressants, the time of onset of the antidepressant response and the limitations of the antidepressants currently available are covered in this monograph. Leading researchers in the area of clinical and experimental psychopharmacology critically assess the progress in their specialist fields. The mechanisms of action of antidepressants are considered, followed by clinical research into the role of the hypothalamic-pituitary-adrenal axis and the immune system in the biology of depression and in response to treatment. The final chapter deals with the important chemical entities now undergoing development as antidepressants. The purpose of this monograph is not only to inform but also to stimulate research into the biology of depression and the mechanisms behind the action of effective antidepressants. This monograph is of interest to psychiatrists, psychologists, pharmacologists, neuroscientists and endocrinologists.

This book fills the void to provide a comprehensive review of the theoretical knowledge and scope of opioid pharmacotherapy in pain medicine. While the information provided is obtainable in other major texts already in print, the present format style plus the illustrations will make easy reading and fast accessibility of information on opioids available. Information provided is based on clinical practice rather than pure experimental for use in daily practice.

For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well.

This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.

Understanding an individual's genetic makeup is the key to creating personalized drugs with greater efficacy and safety, and pharmacogenomics aims to study the complex genetic basis of inter-patient variability in response to drug therapy. Based upon the success of its first edition, the second edition of Pharmacogenomics: Methods And Protocols aims to continue providing readers with high-quality content on the most innovative and commonly adopted technologies in the field of pharmacogenomics as presented by experts in the field. Broken into several sections, this detailed volume examines techniques for interrogating variation in human genes and genomes, functional assessment of genetic variation, both in vitro and in vivo, as well as tools for translation and implementation of pharmacogenetic markers. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to the respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Comprehensive and thoroughly updated, Pharmacogenomics: Methods And Protocols, Second Edition serves as an essential reference and an invaluable source on the latest information in this field.

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.

This latest addition to the Methods in Molecular Medicine series, Anti- ral Methods and Protocols, is opportune because there is an increasing int- est in discovering compounds that are effective against both chronic and acute viral infections. A number of the methods described in the volume are unp- lished and their inclusion indicates the speed at which this field is moving. This volume is not a review but each chapter contains methods validated by the experts who have spent time in developing the protocols. The hallmark of this series is the comprehensive way in which the me- ods are described, which includes a list of all the reagents needed for each protocol. Of importance is the section on tips and pitfalls that the authors have discovered while developing their protocols. The manual itself is designed to be used by researchers in universities and industry who are familiar with a range of biological techniques but who want to set up quickly a novel assay system. We encourage a dialog between readers and authors, which may also result in useful collaborations.

The 2022 edition of the Rules and Guidance for Pharmaceutical Distributors, the 'Green Guide', is the essential reference for all distributors, brokers of human medicines, importers and distributors of active substances in the UK.It provides you with the single authoritative source of European good distribution practices and UK guidance, information and UK legislation on these activities.The new 5th edition has been updated to incorporate changes made after the UK's exit from the European Union on the 31st January 2020.It also incorporates new guidance on pharmacovigilance for wholesalers, the naming of sites on a licence, self-inspection, and the responsible person for import.It brings together EU guidance on good distribution practice and the MHRA's expectations for compliance. There is also a new flowchart for the registration of handling active substances

This book contains contributions presented at the last of the Alcuin Symposia, held in April 2000, as a Festschrift to honour Prof. Axel Wollmer on the occasion of his retirement from the Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen. The Alcuin Symposia were initially held alternatively in York and Aachen, in recent years in Aachen only, as joint workshops on insulin between the groups of Prof. Guy Dodson in York and the groups of Profs Dietrich Brandenburg and Axel Wollmer in Aachen. The Symposium was named after Alcuin, an Anglo-Latin poet, educator and cleric from York, who was invited to join the court of Charlemagne at Aachen. Alcuin's first 50 years were spent in Yorkshire, were he was first a pupil, later headmaster of the cathedral school of York, the most renowned of its day. Charlemagne was gathering at Aachen the leading Irish, English and Italian scholars of the age. Alcuin was appointed head of the Palatine school, where Charlemagne himself, his family, his friends, and his friends's sons were taught. Alcuin introduced the traditions of Anglo-Saxon humanism into Western Europe and was the foremost scholar of the revival of learning known as the Carolingian Renaissance. He also promoted the use of the beautiful Carolingian minuscule script, the ancestor of modern Roman typefaces."

Daydreaming, our ability to give 'to airy nothing a local habitation and a name', remains one of the least understood aspects of human behaviour. As children we explore beyond the boundaries of our experience by projecting ourselves into the mysterious worlds outside our reach. As adolescents and adults we transcend frustration by dreams of achievement or escape, and use daydreaming as a way out of intolerable situations and to help survive boredom, drudgery or routine. In old age we turn back to happier memories as a relief from loneliness or frailty, or wistfully daydream about what we would do if we had our time over again. Why is it that we have the ability to alternate between fantasy and reality? Is it possible to have ambition or the ability to experiment, create or invent without the catalyst of fantasy? Are sexual fantasies an inherent part of human behaviour? Are they universal, healthy, destructive? Is daydreaming itself destructive? Or is it a force which facilitates change and which can even be harnessed to positive advantage? In this provocative book, originally published in 1975, the product of the previous twenty-five years of research, the author debates the nature and function of daydreaming in the light of his own experiments. As well as investigating what is a normal 'fantasy-life' and outlining patterns and types of daydreaming, he describes the role of daydreaming in schizophrenia and paranoia, examines the fantasies and hallucinations induced by drugs and also the nature of altered states of consciousness in Zen and Transcendental Meditation. Among the many topics covered, he explains how it is possible to help children enlarge their capacity for fantasy, how adults can make positive use of daydreaming and how people on the verge of disturbed behaviour are often unconscious of their own fantasies. Advances in scientific methods and new experimental techniques had made it possible at this time to monitor both conscious daydreaming and sub-conscious fantasies in a way not possible before. Professor Singer is one of the few scientists who have conducted substantial research in this area and it is his belief that the study of daydreaming and fantasy is of great importance if we are to understand the workings of the human mind.

Handbook of Analytical Quality by Design addresses the steps involved in analytical method development and validation in an effort to avoid quality crises in later stages. The AQbD approach significantly enhances method performance and robustness which are crucial during inter-laboratory studies and also affect the analytical lifecycle of the developed method. Sections cover sample preparation problems and the usefulness of the QbD concept involving Quality Risk Management (QRM), Design of Experiments (DoE) and Multivariate (MVT) Statistical Approaches to solve by optimizing the developed method, along with validation for different techniques like HPLC, UPLC, UFLC, LC-MS and electrophoresis. This will be an ideal resource for graduate students and professionals working in the pharmaceutical industry, analytical chemistry, regulatory agencies, and those in related academic fields.

A single source for accurate scientific information on herbal remedies! This comprehensive handbook (comprised of two volumes of 700+ pages each) provides a snapshot of 160 herbal products that have been tested in clinical trials. Details of the products and the clinical trials they underwent are here in an easy-to-read, at-a-glance format. Each botanical profile in The Handbook of Clinically Tested Herbal Remedies contains a summary section (table, text and references), followed by product information and clinical trials for that particular product. An evaluation of the strength of the evidence from the trials, along with the context for therapeutics is included to give you a complete picture of each remedy and its usefulness or lack thereof. If there is more than one product based on a particular botanical then the trials are grouped according to the product. This valuable book also makes purchasing easy with manufacturer contact information. With over 30 individual botanicals and 10 multi-ingredient formulas, 160 products and 360 clinical studies, The Handbook of Clinically Tested Herbal Remedies is the book you need to make an informed selection of herbal products. Not only does it list proprietary herbal products that have been tested in controlled clinical studies and provide a rating of the quality of those trials, but, it also describes the fundamentals of herbal medicine, including regulation, characterization, standardization, bioavailability, efficacy, safety, pharmacopoeial monographs as well as incentives, or lack of incentive, for US and European manufacturers to conduct clinical studies. Contributors to the chapters describing the fundamentals of herbal medicine include: * the late Dr. Varro Tyler, Distinguished Professor Emeritus at Purdue University and co-author of Tyler's Honest Herbal, Rational Phytotherapy, and Tyler's Herbs of Choice * Loren Israelsen, JD, president of the LDI group * Tieraona Low Dog, MD, Chair of the USP Dietary Supplement Information Committee * Joerg Grunwald, PhD, co-author of the Physicians Desk Reference (PDR) for Herbal Medicines, and Stefan Spiess, RPh, President of Grunwalder GmbH * Anton Biber, PhD, and Friedrich Lang, PhD, experts in the bioavailability of herbal medicine at Dr. Willmar Schwabe GmbH & Co., Germany * Anthony Almada, MSc, founder and Chief Scientific Officer of IMAGINutrition, Inc. * Joseph M. Betz, PhD, Director of the Dietary Supplements Methods and Reference Materials Program at the NIH Office of Dietary Supplements * Ezra Bejar, PhD, president of Plant Bioassay * Uwe Koetter, PhD, Director of New OTC and Dietary Supplement Product Development at GlaxoSmithKline * Srini Srinivasan, PhD, Vice President of the Dietary Supplement Verification Program of the United States Pharmacopeia (USP) * Roy Upton, Executive Director of the American Herbal Pharmacopoeia. All of the clinical trials in The Handbook of Clinically Tested Herbal Remedies were rated as to their Level of Evidence according to a system designed by Tieraona Low Dog, MD, Chair of the United States Pharmacopoeia Dietary Supplements/Botanicals Expert Panel and a member of the White House Commission on Complementary and Alternative Medicine. The reviewers of the clinical trials included Karriem Ali, MD; Richard Aranda, MD; Elliot Fagelman, MD; Mary Hardy, MD; David Heber, MD, PhD, FACP, FACN; John Trimmer Hicks, MD, FACP, FACR; Hannah Kim, MD; Franklin C. Lowe, MD, MPH; Richard D. O'Connor, MD; Barry S. Oken, M.D; Lynn Shinto, ND; and Keith Wesnes, PhD.

Natural Products in Vector-Borne Disease Management explores the potential application of natural products in vector control and disease management. The chapters discuss the global impact of specific vector-borne diseases, gaps in management, and natural products in specific stages of development - discovery, optimization, validation, and preclinical/clinical development. Toxic effects and mechanisms of action are also discussed. This book also explores how therapeutic plant derivatives can be used to combat the vectors of infection and how natural products can be used to manage and treat vector-borne diseases like malaria, leishmaniasis, dengue, and trypanosomiasis. With the inclusion of case studies on field and clinical applications and the contributions from experts in the field, Natural Products in Vector-Borne Disease Management is an essential resource to researchers, academics, and clinicians in parasitology, virology, microbiology, biotechnology, pharmacology, and pharmacognosy working in the field of vector-borne diseases.

This book details current developments in all natural polymers, with a focus on animal and microbial polysaccharides. The book examines, compares, and contrasts the efficiency of plant and algae based natural polymers in inducing immune reactions. Additionally, the book details the safety and toxicity profiles with respective regulations.